VIR-2703 / Alnylam, Vir Biotech - LARVOL DELTA

Identifying colorectal cancer-specific vulnerabilities in the Wnt-driven long non-coding transcriptome. (PubMed, Gut) - "We propose that cancer-specific Wnt-regulated lncRNAs provide novel therapeutic opportunities to interfere with the Wnt pathway, which has so far defied effective pharmacological inhibition."

Journal • Colorectal Cancer • Oncology • Solid Tumor • CTNNB1 • MYC

Givosiran for the treatment of acute hepatic porphyria. (PubMed, Expert Rev Clin Pharmacol) - "Givosiran is a small interfering RNA (siRNA) therapeutic that reduces hepatic activity of ALAS1 and decreases accumulation of neurotoxic porphyrin precursors in patients with AHPs, ultimately reducing the number of acute attacks and improving symptoms and QoL between attacks. As AHPs are lifelong diseases, long-term safety data are needed for givosiran as an siRNA-based therapy."

Journal • Genetic Disorders • Hematological Disorders • Hepatology • Liver Failure • Metabolic Disorders

Vir and Alnylam identify RNAi therapeutic development candidate, VIR-2703 (ALN-COV), targeting SARS-CoV-2 for the treatment of Covid-19 (Alnylam Press Release) - "Vir Biotechnology, Inc....and Alnylam Pharmaceuticals, Inc....today announced the selection of a development candidate (DC) for VIR-2703 (also referred to as ALN-COV)....The companies plan to soon meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss a potential accelerated path for filing an Investigational New Drug (IND) or IND equivalent application at or around year-end 2020....The companies plan to advance VIR-2703 as an inhalational formulation for the potential treatment and/or prevention of COVID-19....We will further accelerate our efforts and plan to begin studies in humans at or around year-end..."

Clinical • IND • Infectious Disease • Novel Coronavirus Disease